Connect Biopharma Holdings Limited Ordinary Shares (CNTB) is a publicly traded Healthcare sector company. As of May 21, 2026, CNTB trades at $2.35 with a market cap of $134.52M and a P/E ratio of -2.01. CNTB moved +5.71% today. Year to date, CNTB is -3.75%; over the trailing twelve months it is +172.21%. Its 52-week range spans $0.51 to $3.82. Analyst consensus is strong buy with an average price target of $8.38. Rallies surfaces CNTB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Connect Biopharma Raises $20.2M, $46M Cash Funds Seabreeze STAT Phase 2 Data Mid-2026: Connect Biopharma closed a $20.2 million private placement on March 31, 2026, boosting cash to $46 million and funding operations into the second half of 2027. Phase 2 Seabreeze STAT trials of rademikibart in asthma and COPD remain on track per DMC review, with topline data due mid-2026.
| Metric | Value |
|---|---|
| Price | $2.35 |
| Market Cap | $134.52M |
| P/E Ratio | -2.01 |
| EPS | $-1.15 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.82 |
| 52-Week Low | $0.51 |
| Volume | 1.30K |
| Avg Volume | 0 |
| Revenue (TTM) | $233.00K |
| Net Income | $-64.61M |
| Gross Margin | 0.00% |
4 analysts cover CNTB: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.38.